| [1] |
CHEN Hong, CAO Zhiyun.
Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
[J]. China Oncology, 2024, 34(6): 590-597.
|
| [2] |
TAN Xiaolang, YAO Sha, WANG Guihua, PENG Luogen.
Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling
[J]. China Oncology, 2024, 34(10): 944-956.
|
| [3] |
LI Tianjiao, YE Longyun, JIN Kaizhou, WU Weiding, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023
[J]. China Oncology, 2024, 34(1): 1-12.
|
| [4] |
ZENG Cheng, ZHANG Jian.
Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022
[J]. China Oncology, 2023, 33(3): 235-240.
|
| [5] |
FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang.
Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(3): 241-249.
|
| [6] |
YUE Ming, WANG Liwei, CUI Jiujie.
Research progress on the mechanism of organ-specific lung metastasis in pancreatic cancer
[J]. China Oncology, 2023, 33(11): 1026-1031.
|
| [7] |
JIA Yuming, YE Zeng, DENG Yanli, LI Shengchao, ZHANG Zhilei, WANG Chao, XU Xiaowu, QIN Yi, PENG Li.
The research on FBW7 gene enhances antitumor effect of paclitaxel on pancreatic cancer through GSDME-mediated pyroptosis
[J]. China Oncology, 2023, 33(10): 889-897.
|
| [8] |
WANG Xu, CHENG He, LIU Chen, YU Xianjun.
New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022
[J]. China Oncology, 2023, 33(1): 1-13.
|
| [9] |
ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang.
Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study
[J]. China Oncology, 2023, 33(1): 54-60.
|
| [10] |
LI Yujie, CHEN Hao.
Potential of targeting TROP2 in the treatment of pancreatic cancer
[J]. China Oncology, 2022, 32(3): 268-273.
|
| [11] |
WU Mengyin, WU Chunxiao, PANG Yi, WANG Chunfang, GU Kai, GONG Yangming, BAO Pingping, SHI Liang, DOU Jianming, XIANG Yongmei, SHI Yan.
Incidence and mortality of pancreatic cancer in Shanghai 2016 and epidemic trend analysis from 2002 to 2016
[J]. China Oncology, 2022, 32(2): 97-105.
|
| [12] |
LUO Guopei, YU Xianjun.
Precision therapy in pancreatic cancer: from streamlet towards mainstream
[J]. China Oncology, 2022, 32(10): 960-970.
|
| [13] |
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021
[J]. China Oncology, 2022, 32(1): 1-12.
|
| [14] |
YANG Shipeng , LIU Ying , WANG Xinyue , YANG Yang , QUAN Jishu , LIN Zhenhua .
Clinical significance of PKLR overexpression in the pancreatic cancer
[J]. China Oncology, 2021, 31(8): 704-713.
|
| [15] |
TANG Rong, SHI Si, ZHANG Bo, XU Jin, WANG Wei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020
[J]. China Oncology, 2021, 31(1): 1-10.
|
